STOCK TITAN
  1. Home
  2. News
  3. NSPR

InspireMD Inc - NSPR STOCK NEWS

Welcome to our dedicated news page for InspireMD (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on InspireMD.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect InspireMD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of InspireMD's position in the market.

News
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
InspireMD, Inc. (NSPR) announces CEO Marvin Slosman will present at the 23rd Annual Needham Virtual Healthcare Conference. The presentation will focus on the CGuard™ Embolic Prevention Stent System for stroke prevention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
conferences
-
News
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
Rhea-AI Summary
InspireMD, Inc. (NSPR) announces acceptance of one-year outcomes abstract from C-GUARDIANS IDE clinical trial for CGuard™ Prime Carotid Stent System at LINC 2024 conference. Positive 30-day follow-up data revealed low DSMI rates, paving the way for potential Premarket Approval Application and U.S. commercial launch in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
clinical trial
-
News
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
InspireMD, Inc. (NSPR) reported a record fourth-quarter 2023 CGuard EPS revenue of $1.76 million, a 71.6% increase over fourth quarter 2022. The company announced positive 30-day data from its ongoing U.S. Investigational Device Exemption (IDE) clinical trial, C-GUARDIANS, and named lead principal investigators for the C-GUARDIANS II clinical trial. InspireMD also announced key collaborations, including a strategic agreement with the Jacobs Institute and support for the CMS's expanded coverage for CAS. Financially, total revenue for the fourth quarter increased by 71.6%, reaching $1,761,000, with a gross profit increase of 155.1%. However, the company reported a net loss of $5,405,000 for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
earnings
News
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
Rhea-AI Summary
InspireMD, Inc. (NSPR) will announce its fourth quarter and full-year 2023 financial results on March 6th, 2024. The company will host a conference call and webcast to discuss financial results and corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
conferences earnings
-
News
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
Rhea-AI Summary
InspireMD, Inc. (NSPR) appoints principal investigators for upcoming C-GUARDIANS II clinical trial of SwitchGuard™ Neuroprotection System, aiming to support Carotid Artery Stenting and Transcarotid Artery Revascularization procedures. The trial, led by renowned experts in vascular surgery, aims to advance the clearance of SwitchGuard™ NPS for improved patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
management clinical trial
-
News
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
Rhea-AI Summary
InspireMD, Inc. (NSPR) has received CE Mark recertification under the European Union's new Medical Device Regulation for its CGuard™ Embolic Prevention Carotid Stent System. The company is also making progress on the Premarket Approval Application for the C-GUARDIANS U.S. IDE trial and looks forward to primary endpoint results in mid-2024. InspireMD continues to work towards multiple value-creating milestones, including potential U.S. approval of the CGuard Prime EPS stent system in the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
none
News
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
Rhea-AI Summary
InspireMD (Nasdaq: NSPR) appoints Pete Ligotti as Executive Vice President and General Manager of North America, bringing over 30 years of experience in medical technology. The company also grants Mr. Ligotti 138,460 shares of restricted stock and stock options to purchase 46,150 shares of common stock under NASDAQ listing rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
management
-
News
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System
Rhea-AI Summary
InspireMD (Nasdaq: NSPR) announced the issuance of U.S. Patent No. 11,844,893, covering the SwitchGuard™ Neuroprotection System (NPS) for carotid artery disease treatment. The company aims to provide a complete solution set for carotid artery disease and stroke prevention, with a focus on expanding their product portfolio and adding intellectual property to support innovations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
none
-
News
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
Rhea-AI Summary
InspireMD, developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, has entered into a strategic agreement with the Jacobs Institute at the State University of New York at Buffalo and Dr. Adnan Siddiqui to execute an Early Feasibility Study (EFS) evaluating the CGuard EPS carotid stent to treat severe carotid stenosis or occlusion, in conjunction with thrombectomy, in patients presenting with acute ischemic stroke and tandem lesions. The EFS is expected to enroll 15 patients across three U.S. trial sites and explore the safety and feasibility of using the CGuard EPS carotid stent, with its unique MicroNet™ mesh covering, to treat acute ischemic stroke patients with tandem lesions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
none
News
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
InspireMD, Inc. announced positive 30-day results from the C-GUARDIANS U.S. clinical trial, with a major adverse events rate of 0.95%. They also announced support for CMS' final decision to expand coverage of CAS to include more patients. Q3 2023 revenue was $1.56 million, up 9% from Q3 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
earnings
Stock NSPR logo
InspireMD Inc

Nasdaq:NSPR

NSPR Rankings

#4699 Ranked by Market Cap
#49 Ranked by Stock Gains
N/A Ranked by Dividends

NSPR Stock Data

54.42M
10.97M
20.14%
44.08%
0.38%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Israel
4 Menorat Hamaor St

About NSPR

inspiremd, inc. is a company based out of 800 boylston street suite 16041, boston, massachusetts, united states.